| Cover | 12 Months Ended |
| Dec. 31, 2022 | |
| Document Information [Line Items] | |
| Document Type | DEF 14A |
| Amendment Flag | false |
| Entity Information [Line Items] | |
| Entity Registrant Name | Pediatrix Medical Group, Inc. |
| Entity Central Index Key | 0000893949 |
| Pay vs Performance Disclosure Unit_pure in Thousands | 12 Months Ended | ||
| Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) | Dec. 31, 2020 USD ($) | |
| Pay vs Performance Disclosure [Table] | |||
| Pay vs Performance [Table Text Block] | Pay Versus Performance The following table provides pay versus performance information required by Regulation S-K. pay-for-performance Ana Year Summary SCT Total Compensation (2) CAP to Average Non-PEO (3) Average Non-PEO (2)(3) Value of Initial Fixed Income (5) Adjusted (6) Total Peer Group (4) 2022 $ 4,655,746 N/A $ 540,703 N/A $ 1,699,411 $ 364,560 $ 53.47 $ 102.25 $ 62,564 $ 241,033 2021 $ 6,848,969 N/A $ 9,015,601 N/A $ 2,107,197 $ 2,525,213 $ 97.91 $ 138.98 $ 107,987 $ 265,476 2020 (1) $ 6,438,682 $ 7,597,254 $ 6,438,682 $ 4,870,493 $ 3,196,697 $ 2,468,265 $ 88.31 $ 131.41 $ (9,580 ) $ 219,872 (1) In 2020, our Chief Executive Officers were Dr. Medel and Mr. Ordan. (2) Compensation “actually paid” is calculated in accordance with Item 402(v) of Regulation S-K, S-K, (3) During 2022, our non-CEO non-CEO non-CEO (4) The peer group used by the Company consists of the companies used in the Company’s performance graph reported in Part II, Item 5 of its Annual Report on Form 10-K (5) Income (loss) from continuing operations has been used as this is the most appropriate measure of income for the periods. (6) Adjusted EBITDA is the financial measure from the Tabular List of 2022 Most Important Measures shown below, which, in the Company’s assessment, represents for 2022 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 30 and is a non-GAAP Adjustments to Calculate Compensation “Actually Paid” to First PEO (7) 2022 2021 2020 SCT Total $ 4,655,746 $ 6,848,969 $ 6,438,682 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (3,500,013 ) $ (3,500,021 ) $ (4,999,998 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ (615,030 ) $ 5,666,653 $ 4,999,998 CAP Total $ 540,703 $ 9,015,601 $ 6,438,682 Adjustments to Calculate Compensation “Actually Paid” to Second PEO (7) 2020 SCT Total $ 7,597,254 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (6,150,001 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ 3,423,240 CAP Total $ 4,870,493 Adjustments to Calculate Compensation “Actually Paid” to Non-PEO (7) 2022 2021 2020 SCT Total $ 1,699,411 $ 2,107,197 $ 3,196,697 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (1,081,261 ) $ (990,016 ) $ (2,163,436 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ (253,590 ) $ 1,408,032 $ 1,435,004 CAP Total $ 364,560 $ 2,525,213 $ 2,468,265 (7) As shown in these tables, the Compensation “Actually Paid” totals represent the SCT totals for the applicable year, but adjusted as required by SEC rules to include the fair value of current and prior year equity awards that are outstanding, vested or forfeited during the applicable year, instead of the grant date value of awards granted during the applicable year. (8) Represents the total of the amounts reported in the Stock Awards and Option Awards columns of the SCT for the applicable year. (9) The fair value of equity component of the CAP calculation was determined in accordance with SEC methodology for this disclosure. Unlike the SCT, which reflects the grant date fair value of equity awards granted during the applicable year, the CAP table reflects equity fair value as follows: • for awards granted during the applicable year (and which are still outstanding), the year-end • for awards granted during prior years that were still outstanding as of the applicable year-end, applicable year-end prior year-end; • for awards granted in prior years that vested during the applicable year, the change in value as of the vesting date compared against the prior year-end; • for any awards granted in the applicable year that vested during the applicable year, the value as of the vesting date; plus • for any awards that vested during the applicable year, the value of any dividend equivalents that accrued during the vesting period with respect to those awards and were paid out at the same time as the underlying awards, as of the vesting date; minus • for awards granted in prior years that were forfeited during the applicable year, the value as of the prior year-end. The specific calculations with respect to the CAP fair value of equity for the relevant years are shown in the tables below: First PEO – CAP Fair Value of Equity Calculation 2022 2021 2020 YE Value of Current Year Awards Outstanding as of YE $ — $ 4,664,583 $ 3,000,006 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ — $ — $ — Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (1,748,149 ) $ 1,002,070 $ — Value as of Vesting Date for Current Year Awards That Vested During the Year $ 1,133,119 $ — $ 1,999,992 Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — $ — $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — $ — $ — Value of Equity for CAP Purposes $ (615,030 ) $ 5,666,653 $ 4,999,998 Second PEO – CAP Fair Value of Equity Calculation 2020 YE Value of Current Year Awards Outstanding as of YE $ 5,583,464 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ (546,293 ) Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (1,613,931 ) Value as of Vesting Date for Current Year Awards That Vested During the Year $ — Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — Value of Equity for CAP Purposes $ 3,423,240 Non-PEO 2022 2021 2020 YE Value of Current Year Awards Outstanding as of YE $ 350,057 $ 1,310,553 $ 717,561 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ (496,890 ) $ 60,423 $ (37,398 ) Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (106,757 ) $ 37,056 $ (499,755 ) Value as of Vesting Date for Current Year Awards That Vested During the Year $ — $ — $ 1,254,596 Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — $ — $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — $ — $ — Value of Equity for CAP Purposes $ (253,590 ) $ 1,408,032 $ 1,435,004 | ||
| Company Selected Measure Name | Adjusted EBITDA | ||
| Named Executive Officers, Footnote [Text Block] | During 2022, our non-CEO non-CEO non-CEO | ||
| Peer Group Issuers, Footnote [Text Block] | The peer group used by the Company consists of the companies used in the Company’s performance graph reported in Part II, Item 5 of its Annual Report on Form 10-K | ||
| Adjustment To PEO Compensation, Footnote [Text Block] | (6) Adjusted EBITDA is the financial measure from the Tabular List of 2022 Most Important Measures shown below, which, in the Company’s assessment, represents for 2022 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 30 and is a non-GAAP Adjustments to Calculate Compensation “Actually Paid” to First PEO (7) 2022 2021 2020 SCT Total $ 4,655,746 $ 6,848,969 $ 6,438,682 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (3,500,013 ) $ (3,500,021 ) $ (4,999,998 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ (615,030 ) $ 5,666,653 $ 4,999,998 CAP Total $ 540,703 $ 9,015,601 $ 6,438,682 Adjustments to Calculate Compensation “Actually Paid” to Second PEO (7) 2020 SCT Total $ 7,597,254 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (6,150,001 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ 3,423,240 CAP Total $ 4,870,493 First PEO – CAP Fair Value of Equity Calculation 2022 2021 2020 YE Value of Current Year Awards Outstanding as of YE $ — $ 4,664,583 $ 3,000,006 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ — $ — $ — Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (1,748,149 ) $ 1,002,070 $ — Value as of Vesting Date for Current Year Awards That Vested During the Year $ 1,133,119 $ — $ 1,999,992 Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — $ — $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — $ — $ — Value of Equity for CAP Purposes $ (615,030 ) $ 5,666,653 $ 4,999,998 Second PEO – CAP Fair Value of Equity Calculation 2020 YE Value of Current Year Awards Outstanding as of YE $ 5,583,464 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ (546,293 ) Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (1,613,931 ) Value as of Vesting Date for Current Year Awards That Vested During the Year $ — Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — Value of Equity for CAP Purposes $ 3,423,240 | ||
| Non-PEO NEO Average Total Compensation Amount | $ 1,699,411 | $ 2,107,197 | $ 3,196,697 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 364,560 | 2,525,213 | 2,468,265 |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | Adjustments to Calculate Compensation “Actually Paid” to Non-PEO (7) 2022 2021 2020 SCT Total $ 1,699,411 $ 2,107,197 $ 3,196,697 Minus: Grant Date Fair Value of Awards Granted During the Current Year (8) $ (1,081,261 ) $ (990,016 ) $ (2,163,436 ) Plus (Minus): Fair Value of Equity Calculated Using SEC Methodology (9) $ (253,590 ) $ 1,408,032 $ 1,435,004 CAP Total $ 364,560 $ 2,525,213 $ 2,468,265 Non-PEO 2022 2021 2020 YE Value of Current Year Awards Outstanding as of YE $ 350,057 $ 1,310,553 $ 717,561 Change in Value as of YE for Prior Year Awards Outstanding as of YE $ (496,890 ) $ 60,423 $ (37,398 ) Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year $ (106,757 ) $ 37,056 $ (499,755 ) Value as of Vesting Date for Current Year Awards That Vested During the Year $ — $ — $ 1,254,596 Value as of Vesting Date for Dividend Equivalents That Vested During the Year $ — $ — $ — Value as of Prior YE for Prior Year Awards Forfeited During the Year $ — $ — $ — Value of Equity for CAP Purposes $ (253,590 ) $ 1,408,032 $ 1,435,004 | ||
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | As described in more detail in the section “Compensation Discussion and Analysis,” the Company’s executive compensation program reflects a pay-for-performance philosophy. The Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) (“CAP”) for a particular year. The following chart shows the relationship of the compensation actually paid to our PEOs and the average compensation actually paid to our other non-PEO NEOs to the total shareholder return for the Company (“PDX”) and for the S&P 600 Healthcare Index (“S&P 600 HC”). | ||
| Compensation Actually Paid vs. Company Selected Measure [Text Block] | The following chart shows the relationship of the compensation actually paid to our PEOs and the average compensation actually paid to our other non-PEO NEOs as compared to our income (loss) from continuing operations (“IFCO”) and our Adjusted EBITDA (“AEBITDA”). | ||
| Total Shareholder Return Vs Peer Group [Text Block] | As described in more detail in the section “Compensation Discussion and Analysis,” the Company’s executive compensation program reflects a pay-for-performance philosophy. The Company generally seeks to incentivize long-term performance, and therefore does not specifically align the Company’s performance measures with compensation that is actually paid (as computed in accordance with Item 402(v) of Regulation S-K) (“CAP”) for a particular year. The following chart shows the relationship of the compensation actually paid to our PEOs and the average compensation actually paid to our other non-PEO NEOs to the total shareholder return for the Company (“PDX”) and for the S&P 600 Healthcare Index (“S&P 600 HC”). | ||
| Tabular List [Table Text Block] | Tabular List of Most Important Financial Performance Measures We consider the below financial performance measures to be the most important measures used by us to link NEO compensation to Company performance. For further information regarding these performance metrics and their function in our executive compensation program, please see “Compensation Discussion and Analysis.” Most Important Financial Measures • • | ||
| Total Shareholder Return Amount | $ 53.47 | 97.91 | 88.31 |
| Peer Group Total Shareholder Return Amount | 102.25 | 138.98 | 131.41 |
| Net Income (Loss) | $ 62,564,000 | $ 107,987,000 | $ (9,580,000) |
| Company Selected Measure Amount | 241,033 | 265,476 | 219,872 |
| Measure [Axis]: 1 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted EBITDA | ||
| Non-GAAP Measure Description [Text Block] | Adjusted EBITDA is the financial measure from the Tabular List of 2022 Most Important Measures shown below, which, in the Company’s assessment, represents for 2022 the most important performance measure used to link compensation actually paid to our CEOs and other NEOs to the Company’s performance. Adjusted EBITDA is defined on page 30 and is a non-GAAP | ||
| Measure [Axis]: 2 | |||
| Pay vs Performance Disclosure [Table] | |||
| Measure Name | Adjusted Income From Operations | ||
| Dr. Medel [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| PEO Total Compensation Amount | $ 7,597,254 | ||
| PEO Actually Paid Compensation Amount | $ 4,870,493 | ||
| PEO Name | Dr. Medel | ||
| Mr. Ordan [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| PEO Total Compensation Amount | $ 4,655,746 | $ 6,848,969 | $ 6,438,682 |
| PEO Actually Paid Compensation Amount | 540,703 | 9,015,601 | $ 6,438,682 |
| PEO Name | Mr. Ordan | ||
| PEO [Member] | Dr. Medel [Member] | Grant Date [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (6,150,001) | ||
| PEO [Member] | Dr. Medel [Member] | Fair Value of Equity Calculated Using SEC Methodology [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,423,240 | ||
| PEO [Member] | Dr. Medel [Member] | YE Value of Current Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 5,583,464 | ||
| PEO [Member] | Dr. Medel [Member] | Change in Value as of YE for Prior Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (546,293) | ||
| PEO [Member] | Dr. Medel [Member] | Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,613,931) | ||
| PEO [Member] | Dr. Medel [Member] | Value as of Vesting Date for Current Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | ||
| PEO [Member] | Dr. Medel [Member] | Value as of Vesting Date for Dividend Equivalents That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | ||
| PEO [Member] | Dr. Medel [Member] | Value as of Prior YE for Prior Year Awards Forfeited During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | ||
| PEO [Member] | Dr. Medel [Member] | Value of Equity for CAP Purposes [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 3,423,240 | ||
| PEO [Member] | Mr. Ordan [Member] | Grant Date [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (3,500,013) | (3,500,021) | (4,999,998) |
| PEO [Member] | Mr. Ordan [Member] | Fair Value of Equity Calculated Using SEC Methodology [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (615,030) | 5,666,653 | 4,999,998 |
| PEO [Member] | Mr. Ordan [Member] | YE Value of Current Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 4,664,583 | 3,000,006 |
| PEO [Member] | Mr. Ordan [Member] | Change in Value as of YE for Prior Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Mr. Ordan [Member] | Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,748,149) | 1,002,070 | 0 |
| PEO [Member] | Mr. Ordan [Member] | Value as of Vesting Date for Current Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 1,133,119 | 0 | 1,999,992 |
| PEO [Member] | Mr. Ordan [Member] | Value as of Vesting Date for Dividend Equivalents That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Mr. Ordan [Member] | Value as of Prior YE for Prior Year Awards Forfeited During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| PEO [Member] | Mr. Ordan [Member] | Value of Equity for CAP Purposes [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (615,030) | 5,666,653 | 4,999,998 |
| Non-PEO NEO [Member] | Grant Date [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (1,081,261) | (990,016) | (2,163,436) |
| Non-PEO NEO [Member] | Fair Value of Equity Calculated Using SEC Methodology [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (253,590) | 1,408,032 | 1,435,004 |
| Non-PEO NEO [Member] | YE Value of Current Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 350,057 | 1,310,553 | 717,561 |
| Non-PEO NEO [Member] | Change in Value as of YE for Prior Year Awards Outstanding as of YE [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (496,890) | 60,423 | (37,398) |
| Non-PEO NEO [Member] | Change in Value as of Vesting Date for Prior Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | (106,757) | 37,056 | (499,755) |
| Non-PEO NEO [Member] | Value as of Vesting Date for Current Year Awards That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 1,254,596 |
| Non-PEO NEO [Member] | Value as of Vesting Date for Dividend Equivalents That Vested During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Value as of Prior YE for Prior Year Awards Forfeited During the Year [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | 0 | 0 | 0 |
| Non-PEO NEO [Member] | Value of Equity for CAP Purposes [Member] | |||
| Pay vs Performance Disclosure [Table] | |||
| Adjustment to Compensation Amount | $ (253,590) | $ 1,408,032 | $ 1,435,004 |
